Immune checkpoint inhibitor-induced colitis: A comprehensive review

Table 1 Percentage ranges of all grade immune-related common adverse events by checkpoint inhibitor class

Class of immune checkpoint inhibitors	Approved agents	Rash	Diarrhea	Colitis	Elevated ALT	Hypothyroidism	Hypophysitis
Anti CTLA-4	Ipilimumab, Tremelimumab	12%-68%	31%-49%	7%-11.6%	3%-9%	4%-4.2%	4%-6%
Anti PD-1	Nivolumab, Pembrolizumab	11.7%-24%	2.9%-11.5%	1.3%-2.9%	1.8%-7.1%	3.4%-8.5%	0.25%
Anti PD-L1	Atezolizumab, Durvalumab, Avelumab	7.4%	11.6%-23%	0.7%-19.7%	0.9%-4.0%	5.0%-9.6%	0.2%

CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; ALT: Alanine aminotransferase.